

ALLIANCE FOR REGENERATIVE MEDICINE
FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2022
(WITH SUMMARIZED FINANCIAL INFORMATION FOR THE YEAR ENDED
DECEMBER 31, 2021)

ALLIANCE FOR REGENERATIVE MEDICINE

CONTENTS

Independent Auditors' Report	1-2
---	-----

Financial Statements

Statement of Financial Position	3
Statement of Activities.....	4
Statement of Functional Expenses	5
Statement of Cash Flows	6

Notes to Financial Statements	7-14
--	------



INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Alliance for Regenerative Medicine

Opinion

We have audited the financial statements of Alliance for Regenerative Medicine (the Alliance), which comprise the statement of financial position as of December 31, 2022, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Alliance as of December 31, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Alliance and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Alliance's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Alliance's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Alliance's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Matter

The financial statements of the Alliance as of and for the year ended December 31, 2021, were audited by other auditors whose report dated October 18, 2022, expressed an unmodified opinion on those statements. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2021, is consistent, in all material respects with the audited financial statements for which it was derived.

Marcum LLP

Washington, D.C.
December 21, 2023

ALLIANCE FOR REGENERATIVE MEDICINE

STATEMENT OF FINANCIAL POSITION

DECEMBER 31, 2022

(WITH SUMMARIZED FINANCIAL INFORMATION AS OF DECEMBER 31, 2021)

	<u>2022</u>	<u>2021</u>
Assets		
Cash and cash equivalents	\$ 3,500,253	\$ 1,494,630
Investments	6,224,293	6,673,200
Accounts receivable, net	584,893	2,074,250
Prepays and other assets	355,326	493,086
Operating lease right of use asset	836,338	--
Total Assets	<u>\$ 11,501,103</u>	<u>\$ 10,735,166</u>
Liabilities and Net Assets		
Accounts payable and accrued liability	\$ 489,617	\$ 549,544
Accrued compensation	486,905	47,655
Operating lease liability	1,084,240	--
Deferred membership and registration revenue	3,274,521	4,044,150
Deferred lease liability	--	236,826
Total Liabilities	5,335,283	4,878,175
Net Assets without Donor Restrictions	<u>6,165,820</u>	<u>5,856,991</u>
Total Liabilities and Net Assets	<u>\$ 11,501,103</u>	<u>\$ 10,735,166</u>

The accompanying notes are an integral part of these financial statements.

ALLIANCE FOR REGENERATIVE MEDICINE

STATEMENT OF ACTIVITIES

FOR THE YEAR ENDED DECEMBER 31, 2022

(WITH SUMMARIZED FINANCIAL INFORMATION AS OF DECEMBER 31, 2021)

	2022	2021
Revenues and Support		
Membership dues	\$ 7,666,188	\$ 6,531,881
Event income	7,295,519	4,230,827
Investment (loss) income	(491,641)	32,041
Other income	280,230	222,434
Total Revenues and Support	<u>14,750,296</u>	<u>11,017,183</u>
Expenses		
Program services:		
Public affairs, advocacy & communications	5,719,865	3,375,446
Events	4,476,486	2,733,363
Science and technology	1,118,426	555,190
Membership relations	460,266	283,850
Other programs	794,828	390,749
Total Program Services	12,569,871	7,338,598
Supporting services:		
Management and general	1,871,596	1,603,281
Total Expenses	<u>14,441,467</u>	<u>8,941,879</u>
Change in Net Assets	308,829	2,075,304
Net Assets, Beginning of Year	<u>5,856,991</u>	<u>3,781,687</u>
Net Assets, End of Year	<u>\$ 6,165,820</u>	<u>\$ 5,856,991</u>

The accompanying notes are an integral part of these financial statements.

ALLIANCE FOR REGENERATIVE MEDICINE

STATEMENT OF FUNCTIONAL EXPENSES

FOR THE YEAR ENDED DECEMBER 31, 2022

(WITH SUMMARIZED FINANCIAL INFORMATION AS OF DECEMBER 31, 2021)

	Program Services					Total Programs	Supporting Services	2022 Total Expenses	2021 Total Expenses
	Public Affairs, Advocacy & Communications	Events	Science and Technology	Other Programs	Membership Relations		Management and General		
Personnel	\$ 1,652,288	\$ 636,722	\$ 505,576	\$ 28,220	\$ 314,333	\$ 3,137,139	\$ 1,506,085	\$ 4,643,224	\$ 2,981,767
Meeting Expenses	--	3,707,943	--	--	--	3,707,943	--	3,707,943	2,243,385
Professional Fees & Contract Services	1,527,058	12,405	457,837	4,430	81,473	2,083,203	19,493	2,102,696	1,595,041
European Union Section Expenses	1,436,522	--	--	--	--	1,436,522	--	1,436,522	546,383
Retained Consultants	572,852	--	--	721,142	--	1,293,994	124,426	1,418,420	576,734
Other Administrative & Office Expense	257,758	49,293	76,489	17,112	23,957	424,609	116,326	540,935	306,613
Website, Database, & Other IT Expense	100,021	35,007	30,006	12,503	18,891	196,428	55,012	251,440	237,259
Occupancy	84,314	29,510	25,294	10,539	14,755	164,412	46,373	210,785	305,893
Travel Expenses	81,996	3,136	21,107	--	5,622	111,861	--	111,861	20,737
Insurance	7,056	2,470	2,117	882	1,235	13,760	3,881	17,641	28,067
ARM Foundation	--	--	--	--	--	--	--	--	100,000
Total Expenses	<u>\$ 5,719,865</u>	<u>\$ 4,476,486</u>	<u>\$ 1,118,426</u>	<u>\$ 794,828</u>	<u>\$ 460,266</u>	<u>\$ 12,569,871</u>	<u>\$ 1,871,596</u>	<u>\$ 14,441,467</u>	<u>\$ 8,941,879</u>

The accompanying notes are an integral part of these financial statements.

ALLIANCE FOR REGENERATIVE MEDICINE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2022

(WITH SUMMARIZED FINANCIAL INFORMATION AS OF DECEMBER 31, 2021)

	<u>2022</u>	<u>2021</u>
Operating Activities		
Change in net assets	\$ 308,829	\$ 2,075,304
Adjustments to reconcile change in net assets to net cash from operating activities:		
Depreciation	--	556
Amortization of right of use asset	195,891	--
Net unrealized/realized loss (gain) on investments	534,534	(7)
Changes in assets and liabilities:		
Accounts receivable	1,489,357	(1,603,250)
Prepaid and other assets	137,760	224,659
Accounts payable and accrued liability	(59,927)	443,154
Accrued compensation	439,250	20,760
Deferred membership and registration revenue	(769,629)	1,359,905
Operating lease liability	(184,815)	--
Deferred lease liability	--	236,826
Net Cash Provided By Operating Activities	<u>2,091,250</u>	<u>2,757,907</u>
Investing Activities		
Sale of investments	4,222,959	--
Purchase of investments	<u>(4,308,586)</u>	<u>(6,673,193)</u>
Net Cash Used In Investing Activities	<u>(85,627)</u>	<u>(6,673,193)</u>
Net Increase (Decrease) in Cash and Cash Equivalents	2,005,623	(3,915,286)
Cash and Cash Equivalents, Beginning of Year	<u>1,494,630</u>	<u>5,409,916</u>
Cash and Cash Equivalents, End of Year	<u>\$ 3,500,253</u>	<u>\$ 1,494,630</u>

The accompanying notes are an integral part of these financial statements.

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 1 – NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

The Alliance for Regenerative Medicine (the Alliance) was incorporated in 2009 in Washington, D.C. The purpose of the Alliance is to promote legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. The Alliance also works to increase public understanding of the field and its potential to transform human healthcare by providing business development and investor outreach services to support the growth of its member companies and research organizations.

The Alliance's revenue is comprised primarily of membership dues and registration and sponsorship fees for events. The Alliance's membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research, and other alliances supporting regenerative medicine. Members work together to serve as the voice of the global regenerative medicine community and introduce and support policies that pave the way for development of new regenerative medicine therapies, medical devices and diagnostics.

BASIS OF ACCOUNTING

The financial statements are prepared on the accrual basis of accounting and in conformity with accounting principles generally accepted in the United States of America (GAAP).

CASH AND CASH EQUIVALENTS

The Alliance considers all cash and highly liquid investments, with maturities of three months or less, to be cash and cash equivalents.

INVESTMENTS

Investments are recorded at their estimated fair values in the statements of financial position. Realized and unrealized gains and losses, interest, dividends and investment fees arising during the period are included in investment (loss) income in the accompany statement of activities.

FINANCIAL RISK

The Alliance maintains demand deposits with commercial banks. At times, certain balances held within these accounts may not be fully guaranteed or insured by the U.S. federal government. The uninsured portions of cash and money market accounts are backed solely by the assets of the underlying institution. As such, the failure of an underlying institution could result in financial loss to the Alliance.

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 1 – NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

FINANCIAL RISK (CONTINUED)

The Alliance invests in a professionally managed portfolio including mutual funds and money market funds. Such investments are exposed to market and credit risks. The Alliance's investments may be subject to fluctuations in fair value.

ACCOUNTS RECEIVABLE

Accounts receivable consist of membership dues receivable, event sponsorship and fees receivable, and event registration fees receivable. The Alliance recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of specific member/customer accounts, taking into consideration the age of past due accounts and an assessment of the member's/customer's ability to pay. Adjustments to the allowance are recorded through charges to bad debt expense in the accompanying statement of activities. The allowance for doubtful accounts on receivable balances was \$ 55,000 at December 31, 2022 and 2022.

REVENUE RECOGNITION

Revenue recognized from exchange transactions occurs when control of the promised goods or services is transferred to the members or customers in an amount that reflects the consideration the Alliance expects to be entitled to in exchange for those goods or services. For each arrangement with a member or customer, the Alliance identifies the contract and the associated performance obligation(s) within the contract, determines the transaction price of that contract, allocates the transaction price to each performance obligation, and recognizes revenue as each performance obligation is satisfied. For all contracts with members or customers, the Alliance determines the transaction price in the arrangement and allocates the transaction price to each performance obligation identified in the contract. Judgment is applied in determining the appropriate unit of account, and the Alliance separates any performance obligations if they are capable of being distinct and are distinct within the context of the contract. The Alliance determines the allocation of the transaction price for the performance obligations on a relative standalone selling price basis for the goods or services included in the contract. The transaction price is adjusted for estimates of variable consideration. The satisfaction of performance obligations in a contract is based upon when the member or customer obtains control over the asset. Depending on the nature of the performance obligation, control may transfer either at a particular point in time, or over time which determines the recognition pattern of revenue.

The Alliance recognizes revenue from nonrefundable membership dues ratably over the membership term, which is a one-year period. Deferred revenue from membership dues represents the remaining portion of the membership term following the balance sheet date to be recognized ratably into revenues.

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 1 – NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

REVENUE RECOGNITION (CONTINUED)

The Alliance generates event income from registration fees and sponsorships for their different events. The Alliance recognizes registration fees and sponsorship revenue in the period in which the event occurs, which is when the Alliance's performance obligation is met. Registration fees and sponsorships are due in advance of the event. Refunds of registration fees are allowed if received in accordance with the cancellation policy. Registration fees and sponsorships collected in advance of an event are initially recognized as deferred revenue and are only recognized as revenue in the statement of activities when the event has occurred.

FUNCTIONAL ALLOCATION OF EXPENSES

The statement of functional expenses are categorized by function and natural classification. Expenses directly attributable to a specific functional area of the Alliance are reported as expenses of those functional areas. A portion of General and Administrative costs that benefit multiple functional areas have been allocated across Programs and Supporting Services based on a portion of effort of employees to each function.

USE OF ESTIMATES

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts reported in the financial statements and the accompanying notes. Accordingly, actual results could differ from those estimates.

NEW ACCOUNTING PRONOUNCEMENTS

Leases

In February 2016, the Financial Accounting Standards Board (FASB) issued guidance Accounting Standards Codification (ASC) 842, *Leases*, to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (ROU) assets and lease liabilities on the statement of financial position. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Alliance adopted the standard effective January 1, 2022 and recognized and measured leases existing at, or entered into after, January 1, 2022 (the beginning of the period of adoption) through a cumulative effect adjustment, with certain practical expedients available. As a result of the adoption of the new lease accounting guidance, the Alliance recognized on January 1, 2022 a lease liability of \$1,269,055, and an operating lease right-of-use asset of \$1,032,229 (net of deferred rent of \$236,826). The Alliance also derecognized the deferred lease liability of \$236,826 as part of the implementation. Results for periods beginning prior to January 1, 2022, continue to be reported in accordance with ASC 840. The adoption of ASC 842 did not have a material impact on the Association's results of operations and cash flows.

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 1 – NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

RECENT ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, *Financial Instruments - Credit Losses* (Topic 326). ASU 2016-13 changes the impairment model for most financial assets that are measured at amortized cost and certain other instruments from an incurred loss model to an expected loss model. Entities will be required to estimate credit losses over the entire contractual term of an instrument. ASU 2016-13 also includes financial assets recorded at amortized cost basis such as loan receivables, trade and certain other receivables, as well as certain off-balance sheet credit exposures such as loan commitments and financial guarantees. ASU 2016-13 does not apply to financial assets measured at fair value, and loans and receivables between entities under common control.

ASU 2016-13 will be effective for the Alliance beginning January 1, 2023 and early adoption is permitted. The Alliance is evaluating the accounting, transition and disclosure requirements of ASU 2016-13 and cannot currently estimate the financial statement impact of adoption. The Alliance did not adopt the new standard early.

NOTE 2 – INVESTMENTS AND FAIR VALUE MEASUREMENT

GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable input be used when available. Observable inputs are those that market participants would use in measuring investments at fair value based on market data obtained from sources independent of the Alliance. Unobservable inputs reflect the Alliance's assumptions about the inputs market participants would use in measuring investments at fair value based on the best information available in the circumstances. Investments are measured and disclosed in one of the three levels based on the reliability of inputs:

- Level 1: Valuations based on quoted market prices in active markets for identical investments as of the reporting date.
- Level 2: Valuations based on other than quoted market prices in active markets, dealer or broker markets. Fair values are primarily obtained from third party pricing services for similar investments as of the reporting date.
- Level 3: Valuations derived from other methodologies, including pricing models, discounted cash flow models and similar techniques, and not based on market, dealer, or broker-traded transactions. The determination of fair value requires significant management judgment or estimation. Level 3 valuations incorporate certain assumptions and projections that are not observable in the market in determining the fair value for investments and assets held by others as of the reporting date. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level input that is significant to the fair value measurement.

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 2 – INVESTMENTS AND FAIR VALUE MEASUREMENT (CONTINUED)

Investments consisted of the following at December 31, 2022:

	Fair Value	Quoted Prices in Active Markets for Identical Assets/ Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Money market funds	\$ 2,969,433	\$ 2,969,433	\$ --	\$ --
Mutual fund				
Bond funds	1,632,117	1,632,117	--	--
Equity funds	<u>1,622,743</u>	<u>1,622,743</u>	<u>--</u>	<u>--</u>
Total Investments	<u>\$ 6,224,293</u>	<u>\$ 6,224,293</u>	<u>\$ --</u>	<u>\$ --</u>

The following is a description of the valuation techniques used for investments measured at fair value, and there have been no changes in the valuation methodology used by the Alliance at December 31, 2022:

MONEY MARKET FUNDS

Investments held in money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

MUTUAL FUNDS

Mutual funds are valued at the closing price reported on the active market on which the individual securities are traded.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Alliance believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

NOTE 3 - RELATED PARTY TRANSACTIONS

Holland & Knight, LLP, a law firm of which the Co-founder and Senior Policy Counsel of the Alliance is a partner, contracts with the Alliance for services related to the Alliance's policy, lobbying, regulatory and reimbursement counseling. For the year ended December 31, 2022, costs incurred for services rendered by Holland & Knight, LLP were \$605,975.

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 3 - RELATED PARTY TRANSACTIONS (CONTINUED)

The Alliance has a political action committee, Alliance for Regenerative Medicine Political Action Committee (ARMPAC), which is not consolidated with the accounts of the Alliance. The assets and activity of ARMPAC are immaterial for consolidation.

The Alliance is related to ARM Foundation through common board members. ARM Foundation is an organization exempt from payment of income taxes under Section 501(c)(3) of the IRC. Since the Alliance does not have the ability to appoint a controlling interest of members on ARM Foundation's board, the Foundation's financial statements have not been included in these financial statements

NOTE 4 - COMMITMENTS

HOTEL CONTRACTS

During 2022, the Alliance entered into several separate agreements with hotels to reserve rooms and conference space and to provide meals and audio/visual equipment for special events which occurred or will occur. The terms of the agreements call for certain deposits and anticipated minimum amounts to be earned by the hotels, subject to certain cancellation and attrition rights provided to the Alliance. In the event such minimums are not achieved due to cancellations and/or attrition and contingent upon the timing of cancellation and/or the degree of attrition, up to 100% of the liquidated damages, as defined in the agreements, are to be paid by the Alliance. The Alliance's management does not believe that any of these commitments will result in a loss due to liquidated damages. Accordingly, no amount for this potential liability has been reflected in the accompanying financial statements.

NOTE 5 – OPERATING LEASE

In November 2020, the Alliance entered into a lease for office space which expires December 31, 2026, with an option to renew for one additional term of five years. The Alliance has made no decision on the decision to renew the lease. In accordance with the lease agreement, minimum rents are payable in equal monthly installments beginning January 1, 2021 with annual escalations of 2.5% per year thereafter through the end of the lease term.

Lease expense for the year ended December 31, 2022 was \$202,363 and is included in occupancy expense on the Statement of Functional Expense.

The following summarizes the line items in the statement of financial position which include amounts for the operating lease at December 31, 2022:

Operating lease right of use asset	<u>\$ 836,338</u>
Operating lease liability	<u>\$1,084,240</u>

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 5 – OPERATING LEASE (CONTINUED)

The following summarizes the cash flow information related to the operating lease for the year ended December 31, 2022:

Cash paid for amounts included in the measurement of lease liability:	
Operating cash flows from operating lease	<u>\$ 201,354</u>
Operating lease right of use asset obtained in exchange of new lease liability	<u>\$1,032,229</u>

Lease term and discount rate are as follows at December 31, 2022:

Remaining lease term	4 years
Discount rate	1.37%

Future minimum lease commitments are as follows:

<u>For the Year Ending December 31,</u>	
2023	\$ 268,583
2024	275,311
2025	282,199
2026	<u>289,233</u>
Total	1,115,326
Lease: Interest	<u>(31,086)</u>
Total Operating Lease Liability	<u>\$1,084,240</u>

NOTE 6 - RETIREMENT BENEFITS

During January 2019, the Alliance established a Safe Harbor 401(k) Plan (the Plan). Substantially all Alliance employees who have attained the age of 21 and who have at least one year of service, are eligible to participate in the Plan. The Alliance's contribution to the Plan was \$61,171 for the year ended December 31, 2022.

NOTE 7 - LIQUIDITY AND AVAILABILITY OF RESOURCES

The Alliance's financial assets available within one year of the statement of financial position date of December 31, 2022 for general expenditure are as follows:

Cash and cash equivalents	\$ 3,500,253
Investments	6,224,293
Membership and other receivables	<u>584,893</u>
Total Financial Assets Available for General Expenditures Within One Year	<u>\$ 10,309,439</u>

ALLIANCE FOR REGENERATIVE MEDICINE

NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 7 - LIQUIDITY AND AVAILABILITY OF RESOURCES (CONTINUED)

As a part of the Alliance's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

NOTE 8 – INCOME TAXES

The Alliance is exempt from Federal income tax under Section 501(c)(4) of the Internal Revenue Code. Income taxes on unrelated business income, if any, are provided at the applicable rates on income for financial reporting purposes.

The Alliance has adopted the accounting guidance for uncertainty in income taxes. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the position will be sustained upon examination by the tax authorities. As of December 31, 2022, the Alliance had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. The Alliance's income tax filings are subject to audit by various taxing authorities, however, there are no audits currently pending or in process. In evaluating its activities, the Alliance believes its position on tax-exempt status is current based on current facts and circumstances. The Alliance has assessed that there are no activities unrelated to its purpose and, therefore, no tax is to be recognized.

It is the policy of the Alliance to include in expenses, penalties and interest assessed by income taxing authorities. There are no penalties or interest from taxing authorities included in expenses for the year ended December 31, 2022.

NOTE 9 – PRIOR YEAR SUMMARIZED FINANCIAL INFORMATION

The financial statements include certain prior year summarized comparative information in total, but not by net asset class or functional area. Such information does not include sufficient detail to constitute a presentation in conformity with GAAP. Accordingly, such information should be read in conjunction with the Alliance's financial statements for the year ended December 31, 2021, from which the summarized financial information was derived.

NOTE 10 – RECLASSIFICATIONS

Certain 2021 amounts were reclassified to conform with the 2022 presentation.

NOTE 11 - SUBSEQUENT EVENTS

The Alliance has evaluated subsequent events through December 21, 2023 which is the date the financial statements are available to be issued and has determined that there were no subsequent events that have occurred through the date that have not already been recognized or disclosed in these financial statements.